Foresee pharma
Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company committed to improving patients' quality of life and providing cures through innovative research. The company focuses on developing technologies and medicines that offer better comfort, compliance, and convenience, aiming for advancements in healthcare for global needs. Their R&D efforts are centered on a unique Stabilized Injectable Formulation (SIF) long-acting injectable technology and first/best-in-class NCE programs targeting rare and severe diseases with high unmet needs. Driven by purpose and inspired by a better future, Foresee challenges conventions and reimagines possibilities to move science forward and achieve uncompromising advancements for humankind.
Industries
Nr. of Employees
medium (51-250)
Foresee pharma
Products
Stabilized long-acting injectable (SIF) product candidates
Pipeline of stabilized long-acting injectable formulation product candidates derived from a proprietary LAI formulation platform for specialty therapeutic markets.
New chemical entity (NCE) product candidates
Portfolio of small-molecule NCEs in preclinical and clinical development targeting rare, severe and high unmet-need disease areas.
CAMCEVI 42 mg
CAMCEVI 42 mg is a gonadotropin-releasing hormone (GnRH) agonist prefilled syringe injectable emulsion administered subcutaneously every 6 months for advanced prostate cancer.
SIF
Proprietary Stabilized Injectable Formulation (SIF) sustained-release drug delivery platform for long-acting injectable products.
FP-014 (Triptorelin)
FP-014 is a ready-to-use, subcutaneous, long-acting injectable dosage form of triptorelin administered every three or six months for advanced or metastatic prostate cancer and other conditions.
FP-001 42 mg
A stabilized injectable formulation depot injection for central precocious puberty.
Stabilized long-acting injectable (SIF) product candidates
Pipeline of stabilized long-acting injectable formulation product candidates derived from a proprietary LAI formulation platform for specialty therapeutic markets.
New chemical entity (NCE) product candidates
Portfolio of small-molecule NCEs in preclinical and clinical development targeting rare, severe and high unmet-need disease areas.
CAMCEVI 42 mg
CAMCEVI 42 mg is a gonadotropin-releasing hormone (GnRH) agonist prefilled syringe injectable emulsion administered subcutaneously every 6 months for advanced prostate cancer.
SIF
Proprietary Stabilized Injectable Formulation (SIF) sustained-release drug delivery platform for long-acting injectable products.
FP-014 (Triptorelin)
FP-014 is a ready-to-use, subcutaneous, long-acting injectable dosage form of triptorelin administered every three or six months for advanced or metastatic prostate cancer and other conditions.
FP-001 42 mg
A stabilized injectable formulation depot injection for central precocious puberty.
Services
Partnership development to commercialize and launch development-stage and approved pharmaceutical products internationally.
Preparation and publication of periodic financial reports, revenue disclosures and investor communications.
Partnership development to commercialize and launch development-stage and approved pharmaceutical products internationally.
Preparation and publication of periodic financial reports, revenue disclosures and investor communications.
Expertise Areas
- Long-acting injectable formulation development
- Small-molecule drug discovery and preclinical development
- Clinical trial design and execution (Phase II/III)
- CMC and parenteral formulation development
Key Technologies
- Long-acting injectable (LAI) formulation technology
- Small-molecule therapeutics discovery
- Parenteral formulation development
- CMC process development
News & Updates
Foresee presented two posters on pulmonary hypertension and allergen-induced airway responses, with details on timing and location.
Foresee showcased research on asthma and pulmonary hypertension, with details on presentation times and locations.
Foresee announced complete enrollment of its Phase 3 trial for patients with Central Precocious Puberty (CPP).
Foresee announced its participation in the 2024 American Thoracic Society International Conference.
Complete enrollment of the Phase 3 Casppian trial for CPP patients.
Foresee presented two posters on pulmonary hypertension and allergen-induced airway responses, with details on timing and location.
Foresee showcased research on asthma and pulmonary hypertension, with details on presentation times and locations.
Foresee announced complete enrollment of its Phase 3 trial for patients with Central Precocious Puberty (CPP).
Foresee announced its participation in the 2024 American Thoracic Society International Conference.
Complete enrollment of the Phase 3 Casppian trial for CPP patients.